Vaccine Contract Manufacturing Market Report 2022-2032

Publisher Visiongain

Published Apr 13, 2022

Length 565 Pages

SKU # VSG17166144

Description

The Vaccine Contract Manufacturing Market Report 2022-2032

This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Factors Such As Reduced Market Time, Infrastructure Cost Benefits, And Operational Benefits Are Driving The Market Growth

Some of the major forces propelling the global vaccine contract manufacturing market include reduced market time, infrastructure cost, and operational benefits. Furthermore, technical advancements such as the development of new expression systems like GPEx and EB66 cell lines and cell culture medium platforms are expected to propel market growth. On the other hand, few large organizations consider outsourcing to be harmful due to the loss of strategic and management control. Considerable investments in facilities, equipment, and skilled labour in countries looking to grow or localise their supply are expected to impact contract services adoption positively. In addition, several low-resource countries lack the requisite equipment and experienced personnel to manufacture vaccines, leading them to create contracts with contract producers to meet market demand.

On the other hand, few large organizations see outsourcing as a concern since it results in a loss of strategic and management control. As a result, big pharmaceutical companies prefer to maintain their manufacturing in-house. This aspect is predicted to hinder global acceptance of contract services over the forecast period.

Logistical And Administrative Challenges

Local governments will need a robust data infrastructure to identify eligible persons by priority group, make invites, organise transportation for elderly and disabled patients, and recall individuals to obtain second doses of particular vaccines. Several of the most promising vaccine ideas necessitate ultra-cold chains and have a short shelf life once extracted from storage. BioNTech and Pfizer’s mRNA vaccines, for example, must be administered within five days of leaving ultra-low temperature settings (70°C); Moderna’s mRNA vaccine has similar, if less stringent, restrictions. Strong coordination between central depots & local vaccinators would be necessary to ensure the timely & effective delivery of mRNA vaccine batches to regions without freezers.

What Are These Questions You Should Ask Before Buying A Market Research Report?

How is the vaccine contract manufacturing market evolving?
What is driving and restraining the vaccine contract manufacturing market?
How will each vaccine contract manufacturing submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
How will the market shares for each vaccine contract manufacturing submarket develop from 2022 to 2032?
What will be the main driver for the overall market from 2022 to 2032?
Will leading vaccine contract manufacturing markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
Who are the leading players and what are their prospects over the forecast period?
What are the vaccine contract manufacturing projects for these leading companies?
How will the industry evolve during the period between 2020 and 2032? What are the implication of vaccine contract manufacturing projects taking place now and over the next 10 years?
Is there a greater need for product commercialisation to further scale the vaccine contract manufacturing market?
Where is the vaccine contract manufacturing market heading? And how can you ensure you are at the forefront of the market?
What can be the best investment options for new product and service lines?
What are the key prospects for moving companies into a new growth path? C-suite?

You need to discover how this will impact the vaccine contract manufacturing market today, and over the next 10 years:

Our 565-page report provides 377 tables and 379 charts/graphs exclusively to you.
The report highlights key lucrative areas in the industry so you can target them NOW.
Contains in-depth analyse of global, regional and national sales and growth
Highlights for you the key successful trends, changes and revenue projections made by your competitors

This report tells you TODAY how the vaccine contract manufacturing market will develop in the next 10 years, and in-line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2032 and other analyses reveal the commercial prospects

In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
You find original analyses, with business outlooks and developments.
Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising vaccine contract manufacturing prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, V, L, W and U are discussed in this report.

Segments Covered in the Report

Process Outlook

Upstream Process

Mammalian Expression Vaccine

Bacterial Expression Vaccine

Yeast Expression Vaccine

Baculovirus/Insect Expression Vaccine

Other Upstream

Downstream Process

Fill & Finish Operations

Analytical & QC Studies

Vaccine Packaging

Type

Subunit Vaccines
Live Attenuated Vaccines
Conjugate Vaccines
Inactivated Vaccines
Recombinant Vector Vaccines
Other Vaccine Type

Company Size

Small Manufacturers
Mid-sized Manufacturers
Large Manufacturers
Very Large Manufacturers

Operation

Preclinical
Clinical
Commercial
Other Operations

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 4 regional and 20 leading national markets:

North America

U.S.
Canada
Mexico

Europe

Germany
Spain
United Kingdom
France
Italy
Rest of Europe

Asia Pacific

China
Japan
India
Australia
South Korea
Rest of Asia Pacific

LAMEA

Brazil
Turkey
Saudi Arabia
South Africa
UAE
Rest of Latin America

The report also includes profiles and for some of the leading companies in the Vaccine Contract Manufacturing Market, 2022 to 2032, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth

AbbVie Inc. (AbbVie)
Bavarian Nordic A/S
Catalent, Inc.
Charles River Laboratories International, Inc.
Emergent BioSolutions Inc.
Eurofins Scientific SE
FUJIFILM Holdings Corporation
GlaxoSmithKline PLC
Kemwell Biopharma
Lonza Group AG (Lonza)
Merck KGaA
Pfizer Inc. (Pfizer)
Richter-Helm BioLogics
Samsung Biologics Co Ltd
Sanofi SA
Serum Institute of India
Siegfried Holding AG
Thermo Fisher Scientific Inc.
Wacker Biotech B.V
WuXi Biologics Cayman Inc

Overall world revenue for Vaccine Contract Manufacturing Market, 2022 to 2032 in terms of value the market will surpass US$2,676 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Vaccine Contract Manufacturing Market, 2022 to 2032 Market report helps you?

In summary, our 560+ page report provides you with the following knowledge:

Revenue forecasts to 2032 for Vaccine Contract Manufacturing Market, 2022 to 2032 Market, with forecasts for Process, upstream, downstream, type company size each forecasted at a global and regional level discover the industry’s prospects, finding the most lucrative places for investments and revenues
Revenue forecasts to 2032 for 4 regional and 20 key national markets See forecasts for the Vaccine Contract Manufacturing Market, 2022 to 2032 market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
Prospects for established firms and those seeking to enter the market including company profiles for 20 of the major companies involved in the Vaccine Contract Manufacturing Market, 2022 to 2032 Market.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Vaccine Contract Manufacturing Market, 2022 to 2032 Market and leading companies. You will find data, trends and predictions.

1. Report Overview: 1.1 Introduction to Vaccine Contract Manufacturing Market; 1.2 Global Vaccine Contract Manufacturing Market Overview; 1.3 What are the Objectives of this Report?; 1.4 What is the Scope of the Report?; 1.5 Why You Should Read This Report; 1.6 What This Report Delivers; 1.7 Key Questions Answered By This Analytical Report Include:; 1.8 Who is This Report for?; 1.9 Research Methodology; 1.9.1 Primary Research; 1.9.2 Secondary Research; 1.9.3 Market Evaluation & Forecasting Methodology; 1.10 Frequently Asked Questions (FAQs); 1.11 Associated Visiongain Reports; 1.12 About Visiongain
2 Executive Summary
3 Global Market Dynamics: 3.1 COVID-19 Impact on Global Market:; 3.2 Current Trends in the Global Market; 3.3 Market Driving Factors; 3.3.1 Growth In Infectious Diseases; 3.3.2 Stakeholder Cooperation Maximises Manufacturing Capacity; 3.3.3 Implications Beyond COVID-19; 3.4 Market Restraining Factors; 3.4.1 Material And Equipment Shortages; 3.4.2 Manufacturing Process Complexity; 3.4.3 Capacity Constraints; 3.5 Opportunities in the Global Market; 3.5.1 New Vaccine Technologies; 3.5.1.1 Gene-based vaccines; 3.5.1.2 VLPs; 3.5.1.3 Plant-derived vaccines; 3.5.1.4 Novel adjuvants and delivery systems.; 3.6 Challenges in the Global Market; 3.6.1 Unprecedented Vaccine Production Demand; 3.6.2 Logistical And Administrative Challenges; 3.6.3 Vaccine Hesitancy; 3.7 SWOT Analysis; 3.7.1 Strength; 3.7.1.1 Growth In Infectious Diseases; 3.7.1.2 Stakeholder Cooperation Maximises Manufacturing Capacity; 3.7.1.3 Implications Beyond COVID-19; 3.7.2 Weakness; 3.7.2.1 Material And Equipment Shortages; 3.7.2.2 Manufacturing Process Complexity; 3.7.2.3 Capacity Constraints; 3.7.3 Opportunities; 3.7.3.1 New Vaccine Technologies; 3.7.4 Threats; 3.7.4.1 Unprecedented Vaccine Production Demand; 3.7.4.2 Logistical And Administrative Challenges; 3.7.4.3 Vaccine Hesitancy; 3.8 PEST Analysis:; 3.8.1 Political Factors; 3.8.2 Economic Factors; 3.8.3 Sociocultural Factors; 3.8.4 Technological Factors; 3.9 Porter’s Five Forces Analysis; 3.9.1 What are Porter Five (5) Forces; 3.9.2 Threat of New Entrants (Low to Moderate); 3.9.3 Rivalry Among the Existing Players (High); 3.9.4 Bargaining Power of Suppliers (Low); 3.9.5 Threats from Substitute Products (Low to Moderate); 3.9.6 Bargaining Power of Buyers (High)
4 Global Vaccine Contract Manufacturing Market Analysis: 4.1 Global Market Outlook; 4.2 Global Market Size Estimation and Forecast; 4.2.1 Pre-COVID-19 Market Scenario; 4.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
5 Global Vaccine Contract Manufacturing Market Analysis By Region: 5.1 North America; 5.2 Europe; 5.3 Asia Pacific; 5.4 LAMEA; 5.5 Regional Market Size Estimation and Forecast; 5.5.1 Pre-COVID-19 Market Scenario; 5.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
6 Global Vaccine Contract Manufacturing Market Analysis By Process: 6.1 Upstream Process; 6.2 Downstream Process; 6.3 Global Market Size Estimation and Forecast By Process; 6.3.1 Pre-COVID-19 Market Scenario; 6.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
7 Global Vaccine Contract Manufacturing Market Analysis By Downstream: 7.1 Fill & Finish Operations; 7.2 Analytical & QC Studies; 7.3 Vaccine Packaging; 7.4 Global Market Size Estimation and Forecast By Downstream; 7.4.1 Pre-COVID-19 Market Scenario; 7.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
8 Global Vaccine Contract Manufacturing Market Analysis By Upstream: 8.1 Mammalian Expression Vaccine Type; 8.2 Bacterial Expression Vaccine Type; 8.3 Yeast Expression Vaccine Type; 8.4 Baculovirus/Insect Expression Vaccine Type; 8.5 Other Upstream Process; 8.6 Global Market Size Estimation and Forecast By Upstream; 8.6.1 Pre-COVID-19 Market Scenario; 8.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
9 Global Vaccine Contract Manufacturing Market Analysis By Vaccine Type: 9.1 Subunit Vaccines; 9.2 Live Attenuated Vaccines; 9.3 Conjugate Vaccines; 9.4 Inactivated Vaccines; 9.5 Recombinant Vector Vaccines; 9.6 Other Vaccine Type; 9.7 Global Market Size Estimation and Forecast By Vaccine Type; 9.7.1 Pre-COVID-19 Market Scenario; 9.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10 Global Vaccine Contract Manufacturing Market Analysis By Company Size: 10.1 Global Market Size Estimation and Forecast By Company Size; 10.1.1 Pre-COVID-19 Market Scenario; 10.1.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11 Global Vaccine Contract Manufacturing Market Analysis By Operation: 11.1 Preclinical; 11.2 Clinical; 11.3 Commercial; 11.4 Global Market Size Estimation and Forecast By Operation; 11.4.1 Pre-COVID-19 Market Scenario; 11.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12 North America Vaccine Contract Manufacturing Market Analysis: 12.1 North American Countries Have The Most Demanding Legislation Regulating And Controlling Pharmaceuticals’ Distribution And Production; 12.2 North America Market Size Estimation and Forecast; 12.2.1 Pre-COVID-19 Market Scenario; 12.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 12.3 Country Market Size Estimation and Forecast; 12.3.1 Pre-COVID-19 Market Scenario; 12.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 12.4 North America Market Size Estimation and Forecast By Process; 12.4.1 Pre-COVID-19 Market Scenario; 12.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 12.5 North America Market Size Estimation and Forecast By Downstream; 12.5.1 Pre-COVID-19 Market Scenario; 12.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 12.6 North America Market Size Estimation and Forecast By Upstream; 12.6.1 Pre-COVID-19 Market Scenario; 12.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 12.7 North America Market Size Estimation and Forecast By Vaccine Type; 12.7.1 Pre-COVID-19 Market Scenario; 12.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 12.8 North America Market Size Estimation and Forecast By Company Size; 12.8.1 Pre-COVID-19 Market Scenario; 12.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 12.9 North America Market Size Estimation and Forecast By Operation; 12.9.1 Pre-COVID-19 Market Scenario; 12.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 12.10 US Vaccine Contract Manufacturing Market Analysis; 12.10.1 Collaboration Between GSK and Vir Biotechnology to Purchase Additional Supply of Sotrovimab; 12.10.2 Pre-COVID-19 Market Scenario; 12.10.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 12.11 Canada Vaccine Contract Manufacturing Market Analysis; 12.11.1 Emergent Biosolutions Secures Multi-Year Development And Manufacturing Agreement With Providence Therapeutics For Its Mrna COVID-19 Vaccine Candidate, PTX-COVID19-B; 12.11.2 Pre-COVID-19 Market Scenario; 12.11.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 12.12 Mexico Vaccine Contract Manufacturing Market Analysis; 12.12.1 First COVID-19 Vaccine Fill-Finish Manufacturing In Mexico Completed; 12.12.2 Pre-COVID-19 Market Scenario; 12.12.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13 Europe Vaccine Contract Manufacturing Market Analysis: 13.1 EU Watchdog Okays Production Capacity Hikes For J&J, Moderna, Pfizer Vaccines; 13.2 European Commission Approves Contract With Valneva To Secure A New Potential Vaccine; 13.3 Europe Market Size Estimation and Forecast; 13.3.1 Pre-COVID-19 Market Scenario; 13.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 13.4 Country Market Size Estimation and Forecast; 13.4.1 Pre-COVID-19 Market Scenario; 13.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 13.5 Europe Market Size Estimation and Forecast By Process; 13.5.1 Pre-COVID-19 Market Scenario; 13.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 13.6 Europe Market Size Estimation and Forecast By Downstream; 13.6.1 Pre-COVID-19 Market Scenario; 13.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 13.7 Europe Market Size Estimation and Forecast By Upstream; 13.7.1 Pre-COVID-19 Market Scenario; 13.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 13.8 Europe Market Size Estimation and Forecast By Vaccine Type; 13.8.1 Pre-COVID-19 Market Scenario; 13.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 13.9 Europe Market Size Estimation and Forecast By Company Size; 13.9.1 Pre-COVID-19 Market Scenario; 13.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 13.10 Europe Market Size Estimation and Forecast By Operation; 13.10.1 Pre-COVID-19 Market Scenario; 13.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 13.11 Germany Vaccine Contract Manufacturing Market Analysis; 13.11.1 Curevac Slashes COVID-19 Vaccine Production Plans; 13.11.2 Pre-COVID-19 Market Scenario; 13.11.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 13.12 UK Vaccine Contract Manufacturing Market Analysis; 13.12.1 UK Reportedly Selling £200m Vaccine Plant That Never Produced A Single Dose; 13.12.2 Pre-COVID-19 Market Scenario; 13.12.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 13.13 France Vaccine Contract Manufacturing Market Analysis; 13.13.1 Recipharm Secures Vaccine Manufacturing Deal With Top 10 Big Pharma And Will Provide Manufacturing Support From Facility In Kaysersberg, France; 13.13.2 Pre-COVID-19 Market Scenario; 13.13.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 13.14 Italy Vaccine Contract Manufacturing Market Analysis; 13.14.1 Aenova’s Biologics And Vaccines Manufacturing Facility Expansion, Latina, Italy; 13.14.2 Pre-COVID-19 Market Scenario; 13.14.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 13.15 Spain Vaccine Contract Manufacturing Market Analysis; 13.15.1 Moderna And ROVI Expand Long-Term Collaboration For The Manufacture Of MRNA Medicines Over The Next Ten Years; 13.15.2 Pre-COVID-19 Market Scenario; 13.15.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 13.16 Rest of Europe Vaccine Contract Manufacturing Market Analysis; 13.16.1 Pre-COVID-19 Market Scenario; 13.16.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14 Asia-Pacific Vaccine Contract Manufacturing Market Analysis: 14.1 Asia Pacific Must Fix Its Broken Vaccine System; 14.2 Asia-Pacific Market Size Estimation and Forecast; 14.2.1 Pre-COVID-19 Market Scenario; 14.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 14.3 Country Market Size Estimation and Forecast; 14.3.1 Pre-COVID-19 Market Scenario; 14.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 14.4 Asia-Pacific Market Size Estimation and Forecast By Process; 14.4.1 Pre-COVID-19 Market Scenario; 14.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 14.5 Asia-Pacific Market Size Estimation and Forecast By Downstream; 14.5.1 Pre-COVID-19 Market Scenario; 14.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 14.6 Asia-Pacific Market Size Estimation and Forecast By Upstream; 14.6.1 Pre-COVID-19 Market Scenario; 14.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 14.7 Asia-Pacific Market Size Estimation and Forecast By Vaccine Type; 14.7.1 Pre-COVID-19 Market Scenario; 14.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 14.8 Asia-Pacific Market Size Estimation and Forecast By Company Size; 14.8.1 Pre-COVID-19 Market Scenario; 14.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 14.9 Asia-Pacific Market Size Estimation and Forecast By Operation; 14.9.1 Pre-COVID-19 Market Scenario; 14.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 14.10 China Vaccine Contract Manufacturing Market Analysis; 14.10.1 China Is Manufacturing Vaccines In Africa.; 14.10.2 Pre-COVID-19 Market Scenario; 14.10.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 14.11 India Vaccine Contract Manufacturing Market Analysis; 14.11.1 Serum Institute Invests $68m In Oxford Biomedica To Expand Vector Capacity; 14.11.2 Pre-COVID-19 Market Scenario; 14.11.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 14.12 Japan Vaccine Contract Manufacturing Market Analysis; 14.12.1 Japan's Takara Bio To Launch Contract Production Of Mrna Vaccines; 14.12.2 Pre-COVID-19 Market Scenario; 14.12.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 14.13 South Korea Vaccine Contract Manufacturing Market Analysis; 14.13.1 Moderna, Novavax To Produce More COVID-19 Vaccines In South Korea; 14.13.2 South Korea’s SK Bioscience Expands Manufacturing Agreement For Novavax’s COVID-19 Vaccine; 14.13.3 Pre-COVID-19 Market Scenario; 14.13.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 14.14 Australia Vaccine Contract Manufacturing Market Analysis; 14.14.1 Novavax Hunts For Australian Manufacturer As CSL Homes In On AstraZeneca Vaccine Production; 14.14.2 Australia Plans To Stop AstraZeneca Vaccine Production; 14.14.3 Pre-COVID-19 Market Scenario; 14.14.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 14.15 Rest of Asia-Pacific Vaccine Contract Manufacturing Market Analysis; 14.15.1 Pre-COVID-19 Market Scenario; 14.15.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15 LAMEA Vaccine Contract Manufacturing Market Analysis: 15.1 PAHO Welcomes First WHO Emergency Use Listing Of COVID-19 Vaccine Produced In Latin America; 15.2 Brazil And Argentina Tapped To Make mRNA Vaccines In Latin America; 15.3 LAMEA Market Size Estimation and Forecast; 15.3.1 Pre-COVID-19 Market Scenario; 15.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 15.4 Country Market Size Estimation and Forecast; 15.4.1 Pre-COVID-19 Market Scenario; 15.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 15.5 LAMEA Market Size Estimation and Forecast By Process; 15.5.1 Pre-COVID-19 Market Scenario; 15.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 15.6 LAMEA Market Size Estimation and Forecast By Downstream; 15.6.1 Pre-COVID-19 Market Scenario; 15.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 15.7 LAMEA Market Size Estimation and Forecast By Upstream; 15.7.1 Pre-COVID-19 Market Scenario; 15.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 15.8 LAMEA Market Size Estimation and Forecast By Vaccine Type; 15.8.1 Pre-COVID-19 Market Scenario; 15.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 15.9 LAMEA Market Size Estimation and Forecast By Company Size; 15.9.1 Pre-COVID-19 Market Scenario; 15.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 15.10 LAMEA Market Size Estimation and Forecast By Operation; 15.10.1 Pre-COVID-19 Market Scenario; 15.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 15.11 Brazil Vaccine Contract Manufacturing Market Analysis; 15.11.1 Pfizer, Biontech Sign On With Eurofarma Of Brazil For COVID-19 Vaccine Production; 15.11.2 Pre-COVID-19 Market Scenario; 15.11.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 15.12 South Africa Vaccine Contract Manufacturing Market Analysis; 15.12.1 Janssen And Aspen Enter Deal To Manufacture Covid-19 Vaccine In Africa; 15.12.2 Pre-COVID-19 Market Scenario; 15.12.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 15.13 Saudi Arabia Vaccine Contract Manufacturing Market Analysis; 15.13.1 Saudi Arabia Agrees Deal With GSK To Develop Healthcare Sector; 15.13.2 Pre-COVID-19 Market Scenario; 15.13.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 15.14 Turkey Vaccine Contract Manufacturing Market Analysis; 15.14.1 Turkey Renews SK Bioscience’s Vaccine Manufacturing Certification; 15.14.2 Pre-COVID-19 Market Scenario; 15.14.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 15.15 UAE Vaccine Contract Manufacturing Market Analysis; 15.15.1 Mubadala, G42 To Set Up Biopharma Manufacturing Campus In Abu Dhabi; 15.15.2 Pre-COVID-19 Market Scenario; 15.15.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 15.16 Rest of LAMEA Vaccine Contract Manufacturing Market Analysis; 15.16.1 Pre-COVID-19 Market Scenario; 15.16.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16 Company Profiles: 16.1 Catalent; 16.1.1 Company Snapshot; 16.1.2 Company Overview; 16.1.3 Company Financial Profile; 16.1.4 Company Product/Service Benchmarking; 16.1.5 Company Recent Developments; 16.2 Emergent BioSolutions; 16.2.1 Company Snapshot; 16.2.2 Company Overview; 16.2.3 Company Financial Profile; 16.2.4 Company Product/Service Benchmarking; 16.2.5 Company Recent Developments; 16.3 GlaxoSmithKline; 16.3.1 Company Snapshot; 16.3.2 Company Overview; 16.3.3 Company Financial Profile; 16.3.4 Company Product/Service Benchmarking; 16.3.5 Company Recent Developments; 16.4 Lonza Group AG; 16.4.1 Company Snapshot; 16.4.2 Company Overview; 16.4.3 Company Financial Profile; 16.4.4 Company Product/Service Benchmarking; 16.4.5 Company Recent Developments; 16.5 Merck KGaA; 16.5.1 Company Snapshot; 16.5.2 Company Overview; 16.5.3 Company Financial Profile; 16.5.4 Company Product/Service Benchmarking; 16.5.5 Company Recent Developments; 16.6 Pfizer; 16.6.1 Company Snapshot; 16.6.2 Company Overview; 16.6.3 Company Financial Profile; 16.6.4 Company Product/Service Benchmarking; 16.6.5 Company Recent Developments; 16.7 Siegfried Holding; 16.7.1 Company Snapshot; 16.7.2 Company Overview; 16.7.3 Company Financial Profile; 16.7.4 Company Product/Service Benchmarking; 16.7.5 Company Recent Developments; 16.8 Sanofi; 16.8.1 Company Snapshot; 16.8.2 Company Overview; 16.8.3 Company Financial Profile; 16.8.4 Company Product/Service Benchmarking; 16.9 Bavarian Nordic; 16.9.1 Company Snapshot; 16.9.2 Company Overview; 16.9.3 Company Financial Profile; 16.9.4 Company Product/Service Benchmarking; 16.10 FUJIFILM Holdings Corp; 16.10.1 Company Snapshot; 16.10.2 Company Overview; 16.10.3 Company Financial Profile; 16.10.1 Company Product/Service Benchmarking; 16.11 Charles River Laboratories; 16.11.1 Company Snapshot; 16.11.2 Company Overview; 16.11.3 Company Financial Profile; 16.11.4 Company Product/Service Benchmarking; 16.11.5 Company Recent Developments; 16.12 Samsung Biologics; 16.12.1 Company Snapshot; 16.12.2 Company Overview; 16.12.3 Company Financial Profile; 16.12.4 Company Product/Service Benchmarking; 16.12.5 Company Recent Developments; 16.13 AbbVie; 16.13.1 Company Snapshot; 16.13.2 Company Overview; 16.13.3 Company Financial Profile; 16.13.4 Company Product/Service Benchmarking; 16.14 Thermo Fisher Scientific Inc; 16.14.1 Company Snapshot; 16.14.2 Company Overview; 16.14.3 Company Financial Profile; 16.14.4 Company Product/Service Benchmarking; 16.14.5 Company Recent Developments; 16.15 Eurofins Scientific; 16.15.1 Company Snapshot; 16.15.2 Company Overview; 16.15.3 Company Financial Profile; 16.15.4 Company Product/Service Benchmarking; 16.15.5 Company Recent Developments; 16.16 WuXi Biologics; 16.16.1 Company Snapshot; 16.16.2 Company Overview; 16.16.3 Company Financial Profile; 16.16.4 Company Product/Service Benchmarking; 16.16.5 Company Recent Developments; 16.17 Serum Institute of India; 16.17.1 Company Snapshot; 16.17.2 Company Overview; 16.17.3 Company Product/Service Benchmarking; 16.17.4 Company Recent Developments; 16.18 Richter-Helm BioLogics; 16.18.1 Company Snapshot; 16.18.2 Company Overview; 16.18.3 Company Product/Service Benchmarking; 16.18.4 Company Recent Developments; 16.19 Wacker Biotech B.V; 16.19.1 Company Snapshot; 16.19.2 Company Overview; 16.19.3 Company Product/Service Benchmarking; 16.20 Kemwell Biopharma; 16.20.1 Company Snapshot; 16.20.2 Company Overview; 16.20.3 Company Product/Service Benchmarking
17 Conclusion: 17.1 Concluding Remarks; 17.2 Recommendations
List of Tables: Table 1. Global Vaccine Contract Manufacturing Market Forecast, 2022-2032 (USD Mn, AGR (%), CAGR(%)); Table 2. Global Vaccine Contract Manufacturing Market Snapshot, 2022 & 2032 (US$million, CAGR %); Table 3. Global Vaccine Contract Manufacturing Market Forecast, 2022-2032 (USD Mn, AGR (%), CAGR(%)); Table 4. Global Vaccine Contract Manufacturing Market Forecast, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (V – Shaped Recovery); Table 5. Global Vaccine Contract Manufacturing Market Forecast, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (W – Shaped Recovery); Table 6. Global Vaccine Contract Manufacturing Market Forecast, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (U – Shaped Recovery); Table 7. Global Vaccine Contract Manufacturing Market Forecast, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (L – Shaped Recovery); Table 8. Global Vaccine Contract Manufacturing Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)); Table 9. Global Vaccine Contract Manufacturing Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (V – Shaped Recovery); Table 10. Global Vaccine Contract Manufacturing Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (W – Shaped Recovery); Table 11. Global Vaccine Contract Manufacturing Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (U – Shaped Recovery); Table 12. Global Vaccine Contract Manufacturing Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (L – Shaped Recovery); Table 13. Global Vaccine Contract Manufacturing Market by Process, 2022-2032 (USD Mn, AGR (%), CAGR(%)); Table 14. Global Vaccine Contract Manufacturing Market by Process, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (V – Shaped Recovery); Table 15. Global Vaccine Contract Manufacturing Market by Process, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (W – Shaped Recovery); Table 16. Global Vaccine Contract Manufacturing Market by Process, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (U – Shaped Recovery); Table 17. Global Vaccine Contract Manufacturing Market by Process, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (L – Shaped Recovery); Table 18. Global Vaccine Contract Manufacturing Market by Downstream, 2022-2032 (USD Mn, AGR (%), CAGR(%)); Table 19. Global Vaccine Contract Manufacturing Market by Downstream, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (V – Shaped Recovery); Table 20. Global Vaccine Contract Manufacturing Market by Downstream, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (W – Shaped Recovery)

Pricing

Currency Rates

Electronic Access - Single User Fulfilled By Publisher $4,977
Electronic Access - Global Site License Fulfilled by Publisher $8,737
Electronic Access - Site License Fulfilled by Publisher $6,930
Electronic Access - Team 1-6 Users Fulfilled By Publisher $5,670

How Do Licenses Work?

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now